Cantor Fitzgerald Reiterates Overweight on Actinium Pharma, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Actinium Pharma (ATNM) and maintained a $21 price target.
April 30, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Actinium Pharma, with a $21 price target.
The reiteration of an Overweight rating and a high price target by a reputable analyst like Kristen Kluska suggests a strong bullish outlook for Actinium Pharma. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in ATNM's stock price, given the analyst's influence and the significant price target set.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100